Cell & Gene Therapies

(Image: Getty/Ktsimage)

Regeneron in $1bn RNAi pact with Alnylam

By Ben Hargreaves

Regeneron and Alnylam sign discovery agreement that could advance 30 targets within CNS and ocular disorders, during an initial five-year discovery period.

(Image: Getty/NicoElNino)

Yescarta to Europe: Steps learned and production 97% on-spec

By Ben Hargreaves

The difficulties in the manufacture of CAR-T treatments have become increasingly understood as the breakthrough technology has been commercialised, but Kite’s head of medical affairs says its process is nearly flawless.

Follow us

Products

View more

Webinars